Managers / Q1 2022 · view latest →
Boxer Capital, LLC
CIK 0001465837 · 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO, CA, 92130 · (858) 400-3112
Summary
Boxer Capital, LLC reported $1.9B in U.S.-listed holdings across 74 positions for Q1 2022.
Its largest position, MRTXEUR, represents 8.5% of the portfolio.
Compared with Q4 2021, the fund opened 8 new positions and exited 5.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 79.3% · $1.5B
- Other · 12.0% · $234M
- ADR · 5.4% · $106M
- ETP · 3.2% · $63M
- Equity WRT · 0.0% · $220,000
Quarter-over-Quarter Changes full breakdown →
vs Q4 2021 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| APLSUSDApellis Pharmaceuticals Inc | NEW | +1.30M | 1.30M | +$66M | $66M |
| Prometheus Biosciences Inc | NEW | +1.71M | 1.71M | +$65M | $65M |
| RETAEURReata Pharmaceuticals Inc | NEW | +1.24M | 1.24M | +$41M | $41M |
| AMLXAmylyx Pharmaceuticals Inc | NEW | +2.20M | 2.20M | +$28M | $28M |
| Turning Point Therapeutics Inc | NEW | +400.0K | 400.0K | +$11M | $11M |
| TSVT*2Seventy Bio Inc | NEW | +459.8K | 459.8K | +$8M | $8M |
| BLCMEURBellicum Pharmaceuticals Inc | NEW | +57.0K | 57.0K | +$123,000 | $123,000 |
| SRZNWSurrozen Inc | NEW | +66.7K | 66.7K | +$17,000 | $17,000 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2022
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q4 2024 | $0 | 1 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $2.0B | 68 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $1.9B | 61 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $2.0B | 59 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $2.0B | 52 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | Under review | 73 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $2M | 79 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | Under review | 75 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $1.9B | 71 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $1.8B | 73 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $1.6B | 76 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $1.9B | 74 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $2.6B | 71 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $2.9B | 88 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $2.8B | 95 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $2.9B | 85 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $3.1B | 78 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $2.9B | 75 | Nov 17, 2020 | RESTATEMENT | changes · EDGAR ↗ |
| Q2 2020 | $2.3B | 65 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $1.5B | 62 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $1.8B | 51 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $1.4B | 49 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019REVEALED | $1.2B | 37 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $865M | 23 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $809M | 24 | Feb 14, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.